XENOGRAFT AND CELL LINE CORE

异种移植和细胞系核心(核心B)将提供最先进的代表儿童肉瘤组织类型的分子表征的人类模型，将在项目1-3中进行研究。患者来源的异种移植物(PDX)代表尤文肉瘤(n=7)。骨肉瘤(n=10)、横纹肌肉瘤(n=15)和细胞系(n=16)可供研究。通过周期性短串联重复序列(STR)分析和分子图谱分析，确定了核心内线路的真实性和有效性。该中心将根据个别项目的需要，提供皮下、原位和播散性疾病模型，并提供下列服务： 1.维护和鉴定人类异种移植物，并保存经短串联重复序列(STR)分析鉴定的异种移植物的冷冻库存。 2.通过STR分析维护和表征细胞系，以供项目1-3使用。 3.为在所有项目中使用的儿童实体肿瘤异种移植提供繁殖设施。 4.提供原位和播散性异种移植模型，用于二次检测。 5.协调肿瘤移植，并根据需要提供荷瘤小鼠进行药效学和药动学研究。 6.协调治疗和组织收集。 7.使用标准化方案进行药物评价研究，并将数据传输到BioStatics核心。 8.提供其他服务(例如，为PK/PD研究采集血液和组织)。 9.与生物统计核心A协商，协助规划和实验设计。 虽然这是一个新的核心，但核心董事拥有超过35年的开发和使用人类肿瘤异种移植模型的经验，并自2007年以来发表了50篇论文，报告了使用这些模型的新药物的评估。这个

The Xenograft and Cell Line Core (Core B) will provide state of the art molecularly characterized human models representing childhood sarcoma histotypes to be studied in Projects 1-3. Patient derived xenografts (PDX) representing Ewing sarcoma (n=7). Osteosarcoma (n=10) and rhabdomyosarcoma (n=15) and cell lines (n=16) are available for study. Authenticity and validity of lines within the Core have been determined by periodic short tandem repeat (STR) analysis, and molecular profiling. The Core will provide subcutaneous, orthotopic and disseminated disease models as required for individual projects, as well as services listed: 1. Maintain and characterize human xenografts, and maintain frozen stocks of xenografts authenticated by short tandem repeat (STR) analysis. 2. Maintain and characterize cell lines by STR analysis for use in Projects 1-3. 3. To provide a facility for the propagation of xenografts of pediatric solid tumors, for use in all Projects. 4. Provide orthotopic and disseminated xenograft models for secondary testing. 5. Coordinate tumor transplantation and make available tumor-bearing mice for pharmacodynamic and pharmacokinetic studies as required. 6. Coordinate treatment and tissue collection. 7. Undertake drug evaluation studies using standardized protocols, and transfer data to the Biostatics Core. 8. Provide other services (e.g. blood and tissue collection, for PK/PD studies). 9. Assist in planning and experimental design in consultation with the biostatistics Core A. Although this is a new Core, the Core director has over 35 years experience developing and using human tumor xenograft models, and has published 50 papers reporting the evaluation of new agents using these models since 2007. The